Liminatus Pharma, Inc. (LIMN): Nasdaq/NYSE listing notice — Liminatus Pharma receives Nasdaq delisting notice; appeals filed

Liminatus Pharma, Inc.

On May 20, 2026, Nasdaq notified Liminatus Pharma it failed to regain compliance with $50M MVLS and $15M MVPHS requirements.
Trading suspension of common stock (LIMN) and warrants (LIMNW) set for May 29, 2026 unless appeal filed by May 27, 2026.
On May 26, 2026, Company requested a hearing before Nasdaq Hearings Panel, which stays delisting pending hearing.
Company previously disclosed non-compliance on Nov 19, 2025 and had 180-day cure period ending May 18, 2026.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Liminatus Pharma, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5450(b)(2)(C)

Exact text from the filing

May 20, 2026, the Company received a notice from Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will be delisted from The Nasdaq Global Mark

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Liminatus Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-066974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.